SPRING PHARMACEUTICAL GROUP, INC.: 10-Q/A filed 2012-06-12
What SPRING PHARMACEUTICAL GROUP, INC. reported in its quarterly report amendment filed 2012-06-12 (fiscal Q2 2011): 25 published measures, 67 facts as tagged in accession 0001144204-12-034391.
This is an amendment. Values here are as tagged in the amendment; the original filing has its own page.
This filing
- Form
- 10-Q/A (quarterly report amendment)
- Filed
- 2012-06-12
- Fiscal period
- fiscal Q2 2011
- Accession
- 0001144204-12-034391 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; a measure with a published history links to it, and the history shows the latest-filed value per period. All SPRING PHARMACEUTICAL GROUP, INC. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2011-09-30 | 78,582,344 | USD | |
| At 2011-03-31 | 72,109,007 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2011-09-30 | 4,012,904 | USD | |
| At 2011-03-31 | 1,913,505 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2011-09-30 | 74,569,440 | USD | |
| At 2011-06-30 | 71,848,929 | USD | |
| At 2011-03-31 | 70,195,502 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2011-09-30 | 19,697,004 | USD | |
| At 2011-03-31 | 6,046,804 | USD | |
| At 2010-09-30 | 5,576,125 | USD | |
| At 2010-03-31 | 11,911,933 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-07-01 to 2011-09-30 | 2,277,026 | USD | 92 |
| 2011-04-01 to 2011-09-30 | 3,513,178 | USD | 183 |
| 2011-04-01 to 2011-06-30 | 1,236,152 | USD | 91 |
| 2010-07-01 to 2010-09-30 | 1,373,523 | USD | 92 |
| 2010-04-01 to 2010-09-30 | 2,736,763 | USD | 183 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-04-01 to 2011-09-30 | 3,257,862 | USD | 183 |
| 2010-04-01 to 2010-09-30 | 854,565 | USD | 183 |
Capital expenditure payments
Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2010-04-01 to 2010-09-30 | 188,590 | USD | 183 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-04-01 to 2011-09-30 | 9,948,966 | USD | 183 |
| 2010-04-01 to 2010-09-30 | -7,625,777 | USD | 183 |
Income tax expense or benefit
Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-07-01 to 2011-09-30 | 759,009 | USD | 92 |
| 2011-04-01 to 2011-09-30 | 1,171,060 | USD | 183 |
| 2010-07-01 to 2010-09-30 | 484,502 | USD | 92 |
| 2010-04-01 to 2010-09-30 | 943,800 | USD | 183 |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2011-09-30 | 9,800,061 | USD | |
| At 2011-03-31 | 9,629,558 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2010-04-01 to 2010-09-30 | 19,760 | USD | 183 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-07-01 to 2011-09-30 | 2,960,074 | USD | 92 |
| 2011-04-01 to 2011-09-30 | 4,540,103 | USD | 183 |
| 2010-07-01 to 2010-09-30 | 1,858,025 | USD | 92 |
| 2010-04-01 to 2010-09-30 | 3,680,563 | USD | 183 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2011-09-30 | 27,154,694 | USD | |
| At 2011-03-31 | 21,708,245 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2011-09-30 | 4,012,904 | USD | |
| At 2011-03-31 | 1,913,505 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-07-01 to 2011-09-30 | 1,861,709 | USD | 92 |
| 2011-04-01 to 2011-09-30 | 4,643,599 | USD | 183 |
| 2010-07-01 to 2010-09-30 | 780,637 | USD | 92 |
| 2010-04-01 to 2010-09-30 | 1,558,298 | USD | 183 |
Net inventory
Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2011-09-30 | 1,804,397 | USD | |
| At 2011-03-31 | 59,183 | USD |
Gross profit
Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-07-01 to 2011-09-30 | 4,821,783 | USD | 92 |
| 2011-04-01 to 2011-09-30 | 9,183,702 | USD | 183 |
| 2010-07-01 to 2010-09-30 | 2,638,662 | USD | 92 |
| 2010-04-01 to 2010-09-30 | 5,238,861 | USD | 183 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-07-01 to 2011-09-30 | 200,303 | USD | 92 |
| 2011-04-01 to 2011-09-30 | 393,821 | USD | 183 |
| 2010-07-01 to 2010-09-30 | 61,651 | USD | 92 |
| 2010-04-01 to 2010-09-30 | 121,989 | USD | 183 |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2011-09-30 | 36,879,643 | USD | |
| At 2011-03-31 | 36,868,554 | USD |
Accumulated other comprehensive income or loss
Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2011-09-30 | 2,902,053 | USD | |
| At 2011-03-31 | 2,041,293 | USD |
Net intangible assets excluding goodwill
Intangible assets other than goodwill after amortization and impairment. Internally developed intangibles are usually not recognized, so this understates what a company relies on.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2011-09-30 | 41,409,705 | USD | |
| At 2011-03-31 | 40,560,015 | USD |
Comprehensive income or loss
Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-07-01 to 2011-09-30 | 2,720,511 | USD | 92 |
| 2011-04-01 to 2011-09-30 | 4,362,827 | USD | 183 |
| 2010-07-01 to 2010-09-30 | 1,764,859 | USD | 92 |
| 2010-04-01 to 2010-09-30 | 3,272,952 | USD | 183 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-07-01 to 2011-09-30 | 1,049,403 | USD | 92 |
| 2011-04-01 to 2011-09-30 | 2,458,223 | USD | 183 |
| 2010-07-01 to 2010-09-30 | 288,304 | USD | 92 |
| 2010-04-01 to 2010-09-30 | 502,914 | USD | 183 |
Change in inventories
The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-04-01 to 2011-09-30 | 1,745,214 | USD | 183 |
| 2010-04-01 to 2010-09-30 | -287,192 | USD | 183 |
Change in accounts payable
The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2010-04-01 to 2010-09-30 | -2,299,928 | USD | 183 |
Inspect the source
- Entity
- SPRING PHARMACEUTICAL GROUP, INC. / CIK 0000847464
- Captured
- SEC response SHA-256
21fd63bfa4a441f5dd22dbcc8093e88a40c5d63950c8b6833c77a7b4245f4dc7
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0000847464.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))